Pauline Wils

1.4k total citations
43 papers, 417 citations indexed

About

Pauline Wils is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Pauline Wils has authored 43 papers receiving a total of 417 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Genetics, 29 papers in Epidemiology and 11 papers in Surgery. Recurrent topics in Pauline Wils's work include Inflammatory Bowel Disease (42 papers), Microscopic Colitis (27 papers) and Autoimmune and Inflammatory Disorders (6 papers). Pauline Wils is often cited by papers focused on Inflammatory Bowel Disease (42 papers), Microscopic Colitis (27 papers) and Autoimmune and Inflammatory Disorders (6 papers). Pauline Wils collaborates with scholars based in France, United States and Italy. Pauline Wils's co-authors include Maria Nachury, Benjamin Pariente, Laurent Peyrin‐Biroulet, Mathurin Fuméry, Pierre Desreumaux, Anthony Buisson, Julien Branche, Romain Gérard, Silvio Danese and Médina Boualit and has published in prestigious journals such as Gastroenterology, Gut and The American Journal of Gastroenterology.

In The Last Decade

Pauline Wils

37 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pauline Wils France	14	353	276	123	111	41	43	417
Lior Yahav Israel	8	290 0.8×	227 0.8×	124 1.0×	100 0.9×	62 1.5×	20	417
Charlotte I. de Bie Netherlands	8	352 1.0×	246 0.9×	160 1.3×	79 0.7×	36 0.9×	11	425
Natalia López‐Palacios Spain	10	294 0.8×	284 1.0×	177 1.4×	84 0.8×	130 3.2×	18	435
Lorena Rodríguez‐Alonso Spain	10	245 0.7×	237 0.9×	185 1.5×	62 0.6×	28 0.7×	27	421
Francisco Fidencio Cons Molina Colombia	5	283 0.8×	235 0.9×	95 0.8×	120 1.1×	22 0.5×	8	414
Katrien Asnong Belgium	4	343 1.0×	294 1.1×	112 0.9×	61 0.5×	31 0.8×	5	389
Anthony Croft Australia	9	245 0.7×	203 0.7×	77 0.6×	81 0.7×	19 0.5×	17	324
Samira Matri Tunisia	9	178 0.5×	131 0.5×	116 0.9×	86 0.8×	45 1.1×	35	321
Stuart A. Becker Israel	7	254 0.7×	222 0.8×	91 0.7×	101 0.9×	33 0.8×	12	353
Ivan Ferkolj Slovenia	11	276 0.8×	193 0.7×	120 1.0×	111 1.0×	16 0.4×	23	416

Countries citing papers authored by Pauline Wils

Since Specialization

Citations

This map shows the geographic impact of Pauline Wils's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pauline Wils with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pauline Wils more than expected).

Fields of papers citing papers by Pauline Wils

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pauline Wils. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pauline Wils. The network helps show where Pauline Wils may publish in the future.

Co-authorship network of co-authors of Pauline Wils

This figure shows the co-authorship network connecting the top 25 collaborators of Pauline Wils. A scholar is included among the top collaborators of Pauline Wils based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pauline Wils. Pauline Wils is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bureau, Côme, Pauline Wils, E. Merlen, et al.. (2025). Life-threatening immune-related adverse events in the intensive care unit: a narrative review. Intensive Care Medicine. 51(12). 2289–2304.

Wils, Pauline, et al.. (2025). Single-Cell Transcriptomic Profile of Innate Cell Populations in Mesenteric Lymph Nodes of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases. 31(6). 1649–1663. 1 indexed citations

Leroyer, Ariane, Hélène Sarter, Claire Dupont, et al.. (2024). P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study. Journal of Crohn s and Colitis. 18(Supplement_1). i2000–i2000.

Amiot, Aurélien, Philippe Seksik, Antoine Meyer, et al.. (2024). DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial. Journal of Crohn s and Colitis. 18(Supplement_1). i190–i190. 5 indexed citations

Wils, Pauline, Nadia Arab, Aurélien Amiot, et al.. (2024). Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study. Digestive and Liver Disease. 56(8). 1312–1318. 2 indexed citations

Wils, Pauline, Vipul Jairath, Bruce E. Sands, et al.. (2023). Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterology Journal. 11(8). 797–806. 2 indexed citations

Fuméry, Mathurin, Claire Dupont, Delphine Ley, et al.. (2023). Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study. Digestive and Liver Disease. 56(1). 21–28. 3 indexed citations

Buisson, Anthony, Maria Nachury, Clara Yzet, et al.. (2023). Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study. Alimentary Pharmacology & Therapeutics. 59(4). 526–534. 10 indexed citations

Vieujean, Sophie, David Laharie, Anthony Buisson, et al.. (2023). Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study. Digestive and Liver Disease. 56(4). 613–621. 2 indexed citations

10.

Ley, Delphine, Ariane Leroyer, Claire Dupont, et al.. (2023). New Therapeutic Strategies Are Associated With a Significant Decrease in Colectomy Rate in Pediatric Ulcerative Colitis. The American Journal of Gastroenterology. 118(11). 1997–2004. 6 indexed citations

11.

Leroyer, Aurélie S., Claire Dupont, Valérie Bertrand, et al.. (2023). P155 Natural history of anal stricture in pediatric-onset Crohn’s disease: a two-decades population-based study. Journal of Crohn s and Colitis. 17(Supplement_1). i315–i316.

12.

Buisson, Anthony, Maria Nachury, Maud Reymond, et al.. (2022). Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clinical Gastroenterology and Hepatology. 21(9). 2338–2346.e3. 53 indexed citations

13.

Buisson, Anthony, Harry Sokol, Nassim Hammoudi, et al.. (2022). Role of adherent and invasive Escherichia coli in Crohn’s disease: lessons from the postoperative recurrence model. Gut. 72(1). 39–48. 33 indexed citations

14.

Rivière, Pauline, Joel Pekow, Nassim Hammoudi, et al.. (2022). Comparison of the Risk of Crohn’s Disease Postoperative Recurrence Between Modified Rutgeerts Score i2a and i2b Categories: An Individual Patient Data Meta-analysis. Journal of Crohn s and Colitis. 17(2). 269–276. 17 indexed citations

15.

Buisson, Anthony, Maria Nachury, Maud Reymond, et al.. (2022). P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study. Journal of Crohn s and Colitis. 16(Supplement_1). i393–i394. 4 indexed citations

16.

Engel, Tal, Diana E. Yung, Christopher Ma, et al.. (2019). Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Digestive and Liver Disease. 51(9). 1232–1240. 49 indexed citations

17.

Pariente, Benjamin, Nadia Arab, Aurélien Amiot, et al.. (2018). P369 Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre study. Journal of Crohn s and Colitis. 12(supplement_1). S291–S291. 2 indexed citations

18.

Martineau, Chloé, Bernard Flourié, Pauline Wils, et al.. (2017). Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Alimentary Pharmacology & Therapeutics. 46(11-12). 1077–1084. 23 indexed citations

19.

Nachury, Maria, Philippe Zerbib, Romain Gérard, et al.. (2016). Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn’s Disease Patients Classified i2 on the Rutgeerts Score. Digestive Diseases and Sciences. 61(10). 2986–2992. 29 indexed citations

20.

Nachury, Maria, Romain Gérard, Julien Branche, et al.. (2016). Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumab. Digestive and Liver Disease. 49(2). 163–169. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact